- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05192083
A Pilot Trial of a Smartphone-based Self-management Support Program for COPD Patients
A Pilot Trial of a Smartphone-based Self-management Support Program for Patients With Chronic Obstructive Pulmonary Disease
COPD patients often experience multiple symptoms (e.g. dyspnea, cough, and deteriorating quality of life) and have imposed a substantial economic and social burden on health care.
The current proposal is to evaluate the feasibility and acceptability of a pilot trial of a smartphone-based instant messaging self-management support program to improve the quality of life in patients with COPD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Chronic obstructive pulmonary disease (COPD) is the number 3 killer globally by 2020. COPD patients often experience multiple symptoms (e.g. dyspnea, cough, and deteriorating quality of life) and have imposed a substantial economic and social burden on health care.
Current policy for the prevention and management of long-term conditions focuses on efforts to prevent the onset or slow progression of disease early in the disease trajectory. This prevention paradigm has only recently been adopted for COPD. Systematic reviews have shown self-management support for patients with COPD is effective in improving health-related quality of life and in reducing hospital admissions, but the evidence comes largely from patients with moderate or severe disease and is predominantly recruited from secondary care. Simple and systematic strategies are needed to improve out-of-hospital support and management for people living with COPD.
An instant messaging smartphone app, which allows texts, audio, pictures and video messages to be shared in chat groups, is already available to and is the most popular in the Hong Kong general public. Mobile instant messaging can be conducted through a daily use device to increase access and efficacy, which has been suggested as a feasible approach to delivering an intervention with positive effects on health behaviours and outcomes. Text messaging via mobile phones has been shown to be effective in helping promote lifestyle change in diabetes self-management, weight loss, physical activity, smoking cessation and medication adherence with quantitative and qualitative evidence. However, the investigator has not found messaging intervention that was applied in people with COPD, except an ongoing study of using instant text message support for patients with chronic respiratory and cardiovascular diseases.
Hence, the current intervention program is to evaluate the feasibility and acceptability of a smartphone-based instant messaging self-management support program to improve the quality of life in patients with COPD.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Asa Choi, MA
- Phone Number: 852-3917-6563
- Email: asachoi@hku.hk
Study Contact Backup
- Name: Agnes YK Lai, PhD
- Phone Number: 852-3917-6328
- Email: agneslai@hku.hk
Study Locations
-
-
-
Hong Kong, Hong Kong, 852
- Recruiting
- Queen Mary Hospital
-
Contact:
- David Lam, PhD
- Phone Number: 2255-4455
- Email: slnga@hku.hk
-
Contact:
- Agnes Lai, PhD
- Phone Number: 93176779
- Email: agneslai@hku.hk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Aged 18 years and above
- Diagnosis with COPD
- General condition stable
- Able to speak and read Chinese
- Able to complete the self-administered questionnaire
- Able to use instant messages such as WhatsApp or WeChat
- Mental, cognitive and physically fit for joining the trial as determined by the clinician or responsible investigator
- Signed informed consent
Exclusion criteria
- Skeletal fragility
- Serious active infection
- Inability to walk
- Severe respiratory insufficiency
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
The intervention group will receive a smartphone-based self-management support programme, including a 30-min face-to-face or online session at baseline, 3 phone calls (week 2, week 4 and week 6) and 2-month mobile messages in addition to usual care.
|
A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline COPD-related quality of life
Time Frame: Baseline, Week 8
|
COPD symptoms and impacts and activity level were measured by an 8-item COPD Assessment Test.
Total scores range from 0 to 40, with higher scores denoting a more severe impact of COPD on a patient's life.
|
Baseline, Week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline patient activation
Time Frame: Baseline, Week 8
|
Knowledge, skills and confidence in self-management were measured by a 13-item Patient Activation Measure Scale.
The total score ranges from 0 (no activation) to 100 (high activation), with higher scores denoting the better patient activation.
|
Baseline, Week 8
|
|
Change from baseline self-efficacy for self-management
Time Frame: Baseline, Week 8
|
Confidence and perceived ability of self-care were measured by a 6-item Stanford self-efficacy scale.
The score for each item ranges from 1 (not at all confident) to 10 (totally confident).
The total score of the scale is the mean of the six items, with higher number indicates higher self-efficacy.
|
Baseline, Week 8
|
|
Change from baseline acceptance of illness
Time Frame: Baseline, Week 8
|
Acceptance of illness measured by a 8-item acceptance of illness scale.
Each item ranges from 1 to 5. The total score of the scale is between 8 and 40, with low score showing a lack of adjustment to the disease, no acceptance of the condition, and mental discomfort, while high score indicating good disease acceptance.
|
Baseline, Week 8
|
|
Change from baseline medication adherence
Time Frame: Baseline, Week 8
|
Medication adherence measured by a 4-item Morisky Medication-Taking Adherence Scale.
The scale consists of four items with a scoring scheme of "Yes" = 0 and "No" = 1.
All items are summed to give a range of scores from 0 to 4, with higher score indicating a low level of medication adherence.
|
Baseline, Week 8
|
|
Change from baseline physical activity level
Time Frame: Baseline, Week 8
|
Physical activity measured by a 7-item International Physical Activity Questionnaire-short form.
Number of days and duration (in hours and minutes) engaging in vigorous activities, moderate activities, and walking in past 7 days will be collected.
Duration (in hours and minutes) of sitting time on week days and weekends will be collected.
|
Baseline, Week 8
|
|
Change from dyspnea severity
Time Frame: Baseline, week 8
|
Dyspnea severity measured by a 1-item MRC dyspnea scale.
The scale consists of five statements about perceived breathlessness: grade 1, "I only get breathless with strenuous exercise"; grade 2, "I get short of breath when hurrying on the level or up a slight hill"; grade 3, "I walk slower than people of the same age on the level because of breathlessness or have to stop for breath when walking at my own pace on the level"; grade 4, "I stop for breath after walking 100 yards or after a few minutes on the level"; grade 5, " I am too breathless to leave the house".
Patients selected the grade that applied to them.
|
Baseline, week 8
|
|
Change from baseline Health status
Time Frame: Baseline, Week 8
|
Health status measured by a 5-item EuroQol 5-Dimension questionnaire.
The scale comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Each dimension was scored by five levels, with 1 representing no problem and 5 representing extreme problem.
|
Baseline, Week 8
|
|
Change from anxiety and depressive symptoms
Time Frame: Baseline, Week 8
|
Anxiety and depressive symptoms measured by a 14-item Hospital Anxiety and Depression Scale.
Each item ranges from 0-3.
The total scores of both Anxiety and Depression subscales range from 0-21, with higher scores indicating higher level of anxiety and depression respectively.
|
Baseline, Week 8
|
|
Change in baseline social support
Time Frame: Baseline, Week 8
|
Social support measured by a 6-item Multidimensional Scale of Perceived Social Support.
Each item ranges from 1 (very strongly disagree) to 7 (very strongly agree).
The total score is the sum across all items divided by 6, with higher score indicating more social support.
|
Baseline, Week 8
|
|
Change in from baseline sleep quality
Time Frame: Baseline, Week 8
|
Sleep quality measured by a 7-item Insomnia Severity Index.
The total score range from 0 (absence of insomnia) to 28 (severe insomnia).
|
Baseline, Week 8
|
|
Change in baseline grip strength
Time Frame: Baseline, Week 8
|
Grip strength of both hands measured by dynamometer
|
Baseline, Week 8
|
|
Change in baseline balance
Time Frame: Baseline, Week 8
|
Balance assessed by a single-leg stance test.
|
Baseline, Week 8
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Hall AK, Cole-Lewis H, Bernhardt JM. Mobile text messaging for health: a systematic review of reviews. Annu Rev Public Health. 2015 Mar 18;36:393-415. doi: 10.1146/annurev-publhealth-031914-122855.
- Buttery SC, Zysman M, Vikjord SAA, Hopkinson NS, Jenkins C, Vanfleteren LEGW. Contemporary perspectives in COPD: Patient burden, the role of gender and trajectories of multimorbidity. Respirology. 2021 May;26(5):419-441. doi: 10.1111/resp.14032. Epub 2021 Mar 9.
- Jolly K, Sidhu MS, Hewitt CA, Coventry PA, Daley A, Jordan R, Heneghan C, Singh S, Ives N, Adab P, Jowett S, Varghese J, Nunan D, Ahmed K, Dowson L, Fitzmaurice D. Self management of patients with mild COPD in primary care: randomised controlled trial. BMJ. 2018 Jun 13;361:k2241. doi: 10.1136/bmj.k2241.
- Redfern J, Hyun K, Singleton A, Hafiz N, Raeside R, Spencer L, Carr B, Caterson I, Cullen J, Ferry C, Santo K, Hayes A, Leung RWM, Raadsma S, Swinbourne J, Cho JG, King M, Roberts M, Kok C, Jenkins C, Chow C. ITM support for patients with chronic respiratory and cardiovascular diseases: a protocol for a randomised controlled trial. BMJ Open. 2019 Mar 1;9(3):e023863. doi: 10.1136/bmjopen-2018-023863.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UW21-532-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
University of LeicesterUniversity Hospitals, Leicester; University of StrathclydeRecruitingChronic Obstructive Pulmonary Disease (COPD) | Chronic Obstructive Lung Disease | Chronic Obstructive Airway DiseaseUnited Kingdom
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Self-management and Support
-
University of ArkansasPatient-Centered Outcomes Research InstituteCompletedDiabetes Mellitus, Type 2United States
-
Maastricht University Medical CenterAtrium Medical CenterUnknown
-
Université de SherbrookeFonds de la Recherche en Santé du Québec; Agence de la Sante et des Services... and other collaboratorsCompletedChronic DiseasesCanada
-
Johns Hopkins UniversityCompleted
-
University College London HospitalsCompletedNeuromuscular DiseasesUnited Kingdom
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 2 Diabetes MellitusUnited States
-
American Association of Diabetes EducatorsBristol-Myers SquibbUnknownDiabetes Mellitus Type 2United States
-
University of MichiganActive, not recruiting
-
Karen KlassenNational Health and Medical Research Council, Australia; Monash University; The... and other collaboratorsCompletedCardiovascular Disease | HIVAustralia
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveUnited States